EBACW (European Biotech Acquisition) YoY EBITDA Growth: 0.00% (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EBACW European Biotech Acquisition Corp EBACW
22 GF Score
Price $0.52
View Full Analysis

What is European Biotech Acquisition YoY EBITDA Growth?

European Biotech Acquisition EBACW 22 YoY EBITDA Growth is 0.00% as of Dec. 2022. GuruFocus rates EBACW with a GF Score™ of 22/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. European Biotech Acquisition's YoY EBITDA Growth for the quarter that ended in Dec. 2022 was 0.00%.

European Biotech Acquisition's EBITDA per Share for the three months ended in Dec. 2022 was $0.00.

European Biotech Acquisition YoY EBITDA Growth Related Terms

European Biotech Acquisition YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for European Biotech Acquisition's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition YoY EBITDA Growth Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
YoY EBITDA Growth
0.00 0.00

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
YoY EBITDA Growth Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
EBACW
22GF Score
European Biotech Acquisition Corp EBACW
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

European Biotech Acquisition YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

European Biotech Acquisition's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-)/ | |
=N/A %

European Biotech Acquisition's YoY EBITDA Growth for the quarter that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (Q: Dec. 2022 )
=(EBITDA per Share (Q: Dec. 2022 )-EBITDA per Share (Q: Dec. 2021 )) / | EBITDA per Share (Q: Dec. 2021 )) |
=(-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
European Biotech Acquisition (EBACW) has a YoY EBITDA Growth of 0.00% as of Dec. 2022. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for European Biotech Acquisition and its competitors.
Is European Biotech Acquisition's YoY EBITDA Growth too high?
European Biotech Acquisition's current YoY EBITDA Growth is 0.00%. Overall, European Biotech Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does European Biotech Acquisition's YoY EBITDA Growth compare to CNTQ and LION?
European Biotech Acquisition's YoY EBITDA Growth of 0.00% can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Diversified Financial Services company?
A good YoY EBITDA Growth depends on the Diversified Financial Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for European Biotech Acquisition and its competitors. European Biotech Acquisition's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Biotech Acquisition stock overvalued right now?
European Biotech Acquisition (EBACW) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. European Biotech Acquisition's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For European Biotech Acquisition (EBACW), the current YoY EBITDA Growth is 0.00% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

European Biotech Acquisition Business Description

Address EPFL Innovation Park Building, Lausanne, CHE, 1015
European Biotech Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for EBACW

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price